New Perspectives on Obesity-Associated Nephropathy from Pathophysiology to Therapeutics: Revealing the Promise of GLP-1 RA Therapy.
Ren L, Ju F, Liu S, Cai Y, Gang X, Wang G.
Drug Des Devel Ther. 2024 Sep 23;18:4257-4272. doi: 10.2147/DDDT.S476815. eCollection 2024.
Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis.
Darouich S, Goucha R, Jaafoura MH, Zekri S, Ben Maiz H, Kheder A.
Ultrastruct Pathol. 2011 Aug;35(4):176-82. doi: 10.3109/01913123.2011.584657. Epub 2011 Jun 9.
Obesity and renal disease.
Adelman RD.
Curr Opin Nephrol Hypertens. 2002 May;11(3):331-5. doi: 10.1097/00041552-200205000-00010.
The Renal Pathology of Obesity: Structure-Function Correlations.
Tsuboi N, Okabayashi Y.
Semin Nephrol. 2021 Jul;41(4):296-306. doi: 10.1016/j.semnephrol.2021.06.002.
Kidney disease in the obese patient.
Naguib MT.
South Med J. 2014 Aug;107(8):481-5. doi: 10.14423/SMJ.0000000000000141.
Is there an obesity-metabolic syndrome related glomerulopathy?
Ritz E, Koleganova N, Piecha G.
Curr Opin Nephrol Hypertens. 2011 Jan;20(1):44-9. doi: 10.1097/MNH.0b013e3283414ca1.
Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy?
Ahmed MH.
Expert Opin Emerg Drugs. 2006 Nov;11(4):563-5. doi: 10.1517/14728214.11.4.563.
Renal disease in obesity: the need for greater attention.
Rutkowski P, Klassen A, Sebekova K, Bahner U, Heidland A.
J Ren Nutr. 2006 Jul;16(3):216-23. doi: 10.1053/j.jrn.2006.04.017.
Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia.
Verani RR.
Am J Kidney Dis. 1992 Dec;20(6):629-34. doi: 10.1016/s0272-6386(12)70230-5.
Glomerulomegaly and proteinuria in a patient with idiopathic pulmonary hypertension.
Faustinella F, Uzoh C, Sheikh-Hamad D, Truong LD, Olivero JJ.
J Am Soc Nephrol. 1997 Dec;8(12):1966-70. doi: 10.1681/ASN.V8121966.
